S&P 500   4,203.77 (+0.57%)
DOW   32,984.75 (+0.23%)
QQQ   349.31 (+0.38%)
AAPL   179.02 (+1.00%)
MSFT   328.30 (-0.03%)
META   270.82 (+2.30%)
GOOGL   123.18 (+0.25%)
AMZN   121.64 (+0.88%)
TSLA   202.79 (-0.56%)
NVDA   391.30 (+3.43%)
NIO   7.44 (-1.20%)
BABA   82.99 (+4.32%)
AMD   118.09 (-0.10%)
T   15.75 (+0.13%)
F   12.03 (+0.25%)
MU   68.79 (+0.87%)
CGC   0.85 (+1.80%)
GE   103.91 (+2.34%)
DIS   88.18 (+0.25%)
AMC   4.61 (+2.44%)
PFE   38.03 (+0.03%)
PYPL   62.78 (+1.27%)
NFLX   399.74 (+1.14%)
S&P 500   4,203.77 (+0.57%)
DOW   32,984.75 (+0.23%)
QQQ   349.31 (+0.38%)
AAPL   179.02 (+1.00%)
MSFT   328.30 (-0.03%)
META   270.82 (+2.30%)
GOOGL   123.18 (+0.25%)
AMZN   121.64 (+0.88%)
TSLA   202.79 (-0.56%)
NVDA   391.30 (+3.43%)
NIO   7.44 (-1.20%)
BABA   82.99 (+4.32%)
AMD   118.09 (-0.10%)
T   15.75 (+0.13%)
F   12.03 (+0.25%)
MU   68.79 (+0.87%)
CGC   0.85 (+1.80%)
GE   103.91 (+2.34%)
DIS   88.18 (+0.25%)
AMC   4.61 (+2.44%)
PFE   38.03 (+0.03%)
PYPL   62.78 (+1.27%)
NFLX   399.74 (+1.14%)
S&P 500   4,203.77 (+0.57%)
DOW   32,984.75 (+0.23%)
QQQ   349.31 (+0.38%)
AAPL   179.02 (+1.00%)
MSFT   328.30 (-0.03%)
META   270.82 (+2.30%)
GOOGL   123.18 (+0.25%)
AMZN   121.64 (+0.88%)
TSLA   202.79 (-0.56%)
NVDA   391.30 (+3.43%)
NIO   7.44 (-1.20%)
BABA   82.99 (+4.32%)
AMD   118.09 (-0.10%)
T   15.75 (+0.13%)
F   12.03 (+0.25%)
MU   68.79 (+0.87%)
CGC   0.85 (+1.80%)
GE   103.91 (+2.34%)
DIS   88.18 (+0.25%)
AMC   4.61 (+2.44%)
PFE   38.03 (+0.03%)
PYPL   62.78 (+1.27%)
NFLX   399.74 (+1.14%)
S&P 500   4,203.77 (+0.57%)
DOW   32,984.75 (+0.23%)
QQQ   349.31 (+0.38%)
AAPL   179.02 (+1.00%)
MSFT   328.30 (-0.03%)
META   270.82 (+2.30%)
GOOGL   123.18 (+0.25%)
AMZN   121.64 (+0.88%)
TSLA   202.79 (-0.56%)
NVDA   391.30 (+3.43%)
NIO   7.44 (-1.20%)
BABA   82.99 (+4.32%)
AMD   118.09 (-0.10%)
T   15.75 (+0.13%)
F   12.03 (+0.25%)
MU   68.79 (+0.87%)
CGC   0.85 (+1.80%)
GE   103.91 (+2.34%)
DIS   88.18 (+0.25%)
AMC   4.61 (+2.44%)
PFE   38.03 (+0.03%)
PYPL   62.78 (+1.27%)
NFLX   399.74 (+1.14%)
NASDAQ:STAA

STAAR Surgical (STAA) Stock Forecast, Price & News

$57.88
-0.14 (-0.24%)
(As of 11:03 AM ET)
Compare
Today's Range
$56.74
$58.03
50-Day Range
$58.00
$72.82
52-Week Range
$46.35
$112.27
Volume
103,218 shs
Average Volume
663,414 shs
Market Capitalization
$2.80 billion
P/E Ratio
90.44
Dividend Yield
N/A
Price Target
$81.18

STAAR Surgical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.73 Rating Score
Upside/​Downside
39.9% Upside
$81.18 Price Target
Short Interest
Bearish
12.77% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.91mentions of STAAR Surgical in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$51,001 Sold Last Quarter
Proj. Earnings Growth
91.23%
From $0.57 to $1.09 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.65 out of 5 stars

Medical Sector

59th out of 1,006 stocks

Ophthalmic Goods Industry

1st out of 7 stocks


STAA stock logo

About STAAR Surgical (NASDAQ:STAA) Stock

STAAR Surgical Co. engages in the development, manufacture, production, marketing, and sale of implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It specializes in refractive and cataract solutions. Its products include intraocular lens and implantable collamer lens. The company was founded in 1982 and is headquartered in Lake Forest, CA.

Receive STAA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for STAAR Surgical and its competitors with MarketBeat's FREE daily newsletter.

STAA Stock News Headlines

I See Opportunity In STAAR Surgical
ChatGPT Is Already "Old School"
As good as ChatGPT is at writing content, it still doesn't understand what it's saying. But a new AI technology breakthrough will understand and process information like a human. One young company is leading the way.
STAAR Surgical (NASDAQ:STAA) Shares Down 6.1%
What 4 Analyst Ratings Have To Say About Staar Surgical
Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
Brokerages Set STAAR Surgical (NASDAQ:STAA) PT at $82.60
BTIG Remains a Buy on Vicarious Surgical (RBOT)
STAAR Surgical (NASDAQ:STAA) Price Target Raised to $84.00
STAAR Surgical (NASDAQ:STAA) Upgraded at StockNews.com
Analyst Ratings for Staar Surgical
EVO ICL Sponsors Jonas Brothers’ The Tour
BTIG Sticks to Their Buy Rating for Glaukos (GKOS)
See More Headlines

STAA Price History

STAA Company Calendar

Last Earnings
11/03/2021
Today
6/01/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Ophthalmic goods
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:STAA
CUSIP
85231230
Employees
692
Year Founded
1982

Price Target and Rating

Average Stock Price Forecast
$81.18
High Stock Price Forecast
$125.00
Low Stock Price Forecast
$60.00
Forecasted Upside/Downside
+39.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.73
Research Coverage
11 Analysts

Profitability

Net Income
$38.76 million
Pretax Margin
13.15%

Debt

Sales & Book Value

Annual Sales
$284.39 million
Cash Flow
$0.89 per share
Book Value
$7.01 per share

Miscellaneous

Free Float
47,801,000
Market Cap
$2.80 billion
Optionable
Optionable
Beta
1.23

Social Links


Key Executives

  • Thomas G. Frinzi
    Chairman, President & Chief Executive Officer
  • Warren Foust
    Chief Operating Officer
  • Patrick F. WilliamsPatrick F. Williams
    Chief Financial Officer & Vice President
  • Keith HollidayKeith Holliday
    Chief Technology Officer
  • Scott D. Barnes
    Chief Medical Officer













STAA Stock - Frequently Asked Questions

Should I buy or sell STAAR Surgical stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for STAAR Surgical in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" STAA shares.
View STAA analyst ratings
or view top-rated stocks.

What is STAAR Surgical's stock price forecast for 2023?

11 equities research analysts have issued 12 month price targets for STAAR Surgical's shares. Their STAA share price forecasts range from $60.00 to $125.00. On average, they expect the company's share price to reach $81.18 in the next twelve months. This suggests a possible upside of 39.9% from the stock's current price.
View analysts price targets for STAA
or view top-rated stocks among Wall Street analysts.

How have STAA shares performed in 2023?

STAAR Surgical's stock was trading at $48.54 at the beginning of 2023. Since then, STAA stock has increased by 19.5% and is now trading at $58.02.
View the best growth stocks for 2023 here
.

When is STAAR Surgical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our STAA earnings forecast
.

How were STAAR Surgical's earnings last quarter?

STAAR Surgical (NASDAQ:STAA) released its quarterly earnings results on Wednesday, November, 3rd. The medical instruments supplier reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.01. The medical instruments supplier earned $58.35 million during the quarter, compared to the consensus estimate of $57.70 million. STAAR Surgical had a net margin of 10.81% and a trailing twelve-month return on equity of 9.85%. During the same quarter in the prior year, the business earned $0.14 EPS.

What guidance has STAAR Surgical issued on next quarter's earnings?

STAAR Surgical issued an update on its FY 2023 earnings guidance on Wednesday, May, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $348.00 million-$348.00 million, compared to the consensus revenue estimate of $341.43 million.

What is Caren Mason's approval rating as STAAR Surgical's CEO?

6 employees have rated STAAR Surgical Chief Executive Officer Caren Mason on Glassdoor.com. Caren Mason has an approval rating of 68% among the company's employees.

What other stocks do shareholders of STAAR Surgical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other STAAR Surgical investors own include Tesla (TSLA), NVIDIA (NVDA), PayPal (PYPL), Walt Disney (DIS), CrowdStrike (CRWD), DocuSign (DOCU), Shopify (SHOP), Trade Desk (TTD), Teladoc Health (TDOC) and Roku (ROKU).

What is STAAR Surgical's stock symbol?

STAAR Surgical trades on the NASDAQ under the ticker symbol "STAA."

Who are STAAR Surgical's major shareholders?

STAAR Surgical's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.11%), Baillie Gifford & Co. (10.60%), Anatole Investment Management Ltd (4.23%), State Street Corp (3.48%), Palo Alto Investors LP (2.79%) and Geode Capital Management LLC (1.95%). Insiders that own company stock include Broadwood Partners, LP, Caren L Mason, Graydon C Hansen, Hans-Martin Blickensdoerfer, James E Francese, Jon K Hayashida, Keith Holliday, Patrick F Williams and Samuel J Gesten.
View institutional ownership trends
.

How do I buy shares of STAAR Surgical?

Shares of STAA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is STAAR Surgical's stock price today?

One share of STAA stock can currently be purchased for approximately $58.02.

How much money does STAAR Surgical make?

STAAR Surgical (NASDAQ:STAA) has a market capitalization of $2.80 billion and generates $284.39 million in revenue each year. The medical instruments supplier earns $38.76 million in net income (profit) each year or $0.64 on an earnings per share basis.

How many employees does STAAR Surgical have?

The company employs 692 workers across the globe.

Does STAAR Surgical have any subsidiaries?
The following companies are subsidiares of STAAR Surgical: Canon Staar, Frigitronics Inc., STAAR Japan Inc., STAAR Optical Equipment, STAAR Surgical AG, STAAR Surgical PTE. LTD, and Technology (Shanghai) Co. LTD.
Read More
How can I contact STAAR Surgical?

STAAR Surgical's mailing address is 25651 ATLANTIC OCEAN DRIVE, LAKE FOREST CA, 92630. The official website for the company is www.staar.com. The medical instruments supplier can be reached via phone at (626) 303-7902, via email at bmoore@staar.com, or via fax at 626-303-2962.

This page (NASDAQ:STAA) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -